Instrument Inactif

Communiqués Concert Pharmaceuticals, Inc.

Actions

CNCE

US2060221056

Recherche biotechnologique et médicale

Communiqués

27/09/23	Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	AQ
20/03/23	SUN PHARMA - LATE-BREAKING PHASE 3 DATA AT AAD 2023 SHOW ORAL INVESTIGATIONAL MEDICINE DEURUXOLITINIB SIGNIFICANTLY IMPROVED SCALP HAIR REGROWTH IN ALOPECIA AREATA	AQ
06/03/23	CONCERT PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
15/02/23	Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	BU
20/01/23	CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE	BU
19/01/23	CONCERT PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/01/23	Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata	BU
21/11/22	Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research	BU
09/11/22	Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference	BU
07/11/22	CONCERT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
07/11/22	Concert: Q3 Earnings Snapshot	AQ
07/11/22	Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results	BU
31/10/22	Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022	BU
12/09/22	CONCERT PHARMACEUTICALS ANNOUNCES PRESENTATION OF CTP-543 THRIVE-AA1 PHASE 3 DATA IN ALOPECIA AREATA DURING LATE BREAKING SESSION AT EADV CONGRESS	AQ
10/09/22	Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress	BU
06/09/22	Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference	BU
01/09/22	Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata	BU
22/08/22	CONCERT PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
22/08/22	Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress	BU
22/08/22	Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement	BU
04/08/22	Concert: Q2 Earnings Snapshot	AQ
04/08/22	Concert Pharmaceuticals : Reports Second Quarter 2022 Financial Results - Form 8-K	PU
04/08/22	CONCERT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/22	CONCERT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/08/22	Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results	BU